- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What Are the Next Steps for Collaboration, Accountability in Oncology Care First?
On this episode of Managed Care Cast, we speak with Kashyap Patel, MD, the chief executive officer of Carolina Blood and Cancer Care Associates—a leading OCM practice—and associate editor of Evidence-Based Oncology™ (EBO), as well as Tennessee Oncology’s Stephen M. Schleicher, MD, MBA, to discuss Oncology Care First.
Participants in the Oncology Care Model (OCM) have speculated greatly about what will come after the 5-year pilot program ends on June 30, 2021. The suspense ended November 1, 2019, when the Center for Medicare & Medicaid Innovation (CMMI) unveiled a request for information regarding Oncology Care First (OCF), a proposed successor model that would build on the lessons learned from OCM.
On this episode of Managed Care Cast, we speak with Kashyap Patel, MD, the chief executive officer of Carolina Blood and Cancer Care Associates—a leading OCM practice—and associate editor of Evidence-Based Oncology™ (EBO), as well as Tennessee Oncology’s Stephen M. Schleicher, MD, MBA, to discuss the proposal and what comes next.
Listen above or or through one of these podcast services:
Read more:
CMS, CMMI Seek Feedback on Oncology Care First, Successor to OCM
Electronic PROs a Proposed Feature of Successor Model in Oncology Care
Provider Perspective: Kashyap Patel, MD, Sees Collaboration Going Into Oncology Care First
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More
